Taysha Gene Therapies (TSHA) insider plans Rule 144 sale worth $855K

Rhea-AI Filing Summary

Taysha Gene Therapies insider plans Rule 144 sale of stock. A holder has filed to sell 168,078 shares of Taysha Gene Therapies common stock through broker Maxim Group LLC on or about 01/23/2026, with an indicated aggregate market value of $855,517.02. The filing notes that 273,919,373 shares of common stock were outstanding, providing context for the size of the planned sale. The shares to be sold were acquired on 01/23/2026 via a restricted stock unit (RSU) award from the issuer, which vested and was settled in stock as compensation for the reporting person’s continued service as an employee.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Maxim Group LLC 300 Park Avenue, 16th Floor New York NY 10022	168078	855517.02	273919373	01/23/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/23/2026	RSU Award	Issuer			168078	01/23/2026	Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TSHA Form 144 filing disclose?

The filing discloses a planned sale of 168,078 shares of Taysha Gene Therapies common stock under Rule 144, to be executed through Maxim Group LLC on or about 01/23/2026.

How many Taysha Gene Therapies (TSHA) shares are involved and what is their value?

The planned Rule 144 sale covers 168,078 common shares with an indicated aggregate market value of $855,517.02.

How were the TSHA shares in this Form 144 acquired?

The 168,078 shares were acquired on 01/23/2026 via an RSU award from the issuer, described as a vested grant settled in stock in exchange for the reporting person’s continued service as an employee.

What does the Form 144 say about Taysha Gene Therapies shares outstanding?

The notice states that 273,919,373 shares of Taysha Gene Therapies common stock were outstanding, giving context for the size of the planned sale.

On which exchange are the TSHA shares being sold under this Form 144?

The planned sale of Taysha Gene Therapies common stock is listed as taking place on the Nasdaq stock market.

Who is the broker for the TSHA Form 144 stock sale?

The broker named for the planned Rule 144 sale is Maxim Group LLC, located at 300 Park Avenue, 16th Floor, New York, NY 10022.